DON HARDISON, President and Chief Executive Officer, Good Start Genetics >>
ROBERT S. LANGER, Sc.D., Institute Professor, Massachusetts Institute of Technology >>
PAUL MAEDER, General Partner, Highland Capital Partners >>
JAY MOORIN, General Partner, ProQuest Investments >>
MARSHA A. MOSES, Ph.D. (Co-Founder), Julia Dyckman Andrus Professor, Harvard Medical School and Director, Vascular Biology Program, Children's Hospital Boston >>
PIERRE CASSIGNEUL, Chief Executive Officer, Predictive Biosciences >>
General Partner, Flybridge Capital Partners
Mr. Greeley founded Flybridge Capital Partners and is a General Partner focusing on information technology, healthcare and medical technology investments. Michael currently represents Flybridge Capital Partners on the boards of BlueTarp, MicroCHIPS, Predictive Biosciences, ProteinForest and VidSys, and led the firm's investment in T2 Biosystems and Magen BioSciences.
Prior to founding Flybridge Capital Partners, Michael was with Polaris Venture Partners, where he focused on both early-stage and later-stage financings for emerging growth companies. Before Polaris, he served for over five years as Senior Vice President and Founding Partner of GCC Investments, a successful $200 million private equity fund. Prior to GCC Investments, Michael was a Vice President and one of the early professionals at Wasserstein Perella & Co., an international merchant bank with a $1.0 billion private equity fund. Additionally, Michael was a member of the Mergers and Acquisitions Department of Morgan Stanley & Co. and worked in the Leveraged Buyout Group of Credit Suisse First Boston.
In previous positions, Michael has served on the Boards of a number of public and private companies including Global TeleSystems Group (NASDAQ: GTSG), El Sitio International (NASDAQ: LCTO), MotherNature.com (NASDAQ: MTHR), Crescent Communications (acquired by Clear Channel), Fleetcor Technologies and American Capital Access. He currently serves as the President of the New England Venture Capital Association, is a member of the Executive Business Advisory Council for Mass General Hospital for Children, and is a trustee and on the investment committee of the Massachusetts Eye and Ear Infirmary.
Michael received a B.A. with honors in chemistry from Williams College and an MBA from Harvard Business School.
General Partner, New Enterprise Associates (NEA)
Dr. Barrett joined New Enterprise Associates (NEA) in 2001 as a General Partner. Jim specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. In addition to Predictive, he currently resides on the board of directors for Cardioxyl Pharmaceuticals, GlycoMimetics, Inc., Inhibitex, Inc. (NASDAQ: INHX), Nucleonics, Inc., Peptimmune, Inc., Proteostasis Therapeutics, Inc., Ruxton Pharmaceuticals, Sensors for Medicine and Science, Inc., Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT) and Zosano Pharma, Inc.
Prior to joining NEA, Jim served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001), where he remains Chairman. Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995); President and CEO of Life Technologies (1985 - 1987); and President and CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, he worked in various divisions of SmithKline.
Jim received his Ph.D. in biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a B.S. in chemistry from Boston College.
President and Chief Executive Officer, Good Start Genetics
Mr. Hardison is the Chief Executive Officer and a member of the board of Good Start Genetics. Don is an executive with broad private and public company backgrounds in both emerging and Fortune 500 companies. Prior to joining Good Start Genetics, he was at Laboratory Corporation of America in Burlington, North Carolina, where he served as an Executive Vice President & Chief Operating Officer. Don has served as President, CEO and Director of EXACT Corporation, an applied genomics/biotechnology company focused on the early detection of cancer. Over the past 30 years, he also has worked as a Managing Partner of OnTarget, a sales and marketing consulting firm, and has held numerous leadership roles at Quest Diagnostics and SmithKline Beecham Corporation. He holds a bachelor’s degree from the University of North Carolina, Chapel Hill.
Institute Professor, Massachusetts Institute of Technology
Dr. Langer is one of 13 Institute Professors (the highest rank awarded to a faculty member) at the Massachusetts Institute of Technology (MIT).
Bob has written more than 900 articles and has more than 550 issued or pending patents worldwide (one of which was cited as the outstanding patent in Massachusetts in 1988 and one of 20 outstanding patents in the United States.). He has received nearly 150 major awards, including the Gairdner Foundation International Award (68 recipients have subsequently received a Nobel Prize), the Lemelson-MIT Prize (the world's largest prize for invention), and the Charles Stark Draper Prize (the world's most prestigious engineering prize, from the National Academy of Engineering). In 1989, Bob was elected to the Institute of Medicine and the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. Forbes Magazine (1999) and Bio World (1990) have named him as one of the 25 most important individuals in biotechnology in the world.
Bob has received honorary doctorates from multiple institutions. He received a bachelor's degree from Cornell University in 1970 and his Sc.D. from MIT in 1974, both in chemical engineering.
General Partner, Highland Capital Partners
Mr. Maeder is a former director of Amp Resources (acquired by Enel), Avid Technology (Nasdaq: AVID), Bit9, CheckFree (Nasdaq: CKFR), Chipcom, HighGround Systems, (acquired by Sun Microsystems), Mainspring (acquired by IBM), Relicore (acquired by Symantec), SCH (acquired by Legato Systems), SQA (acquired by Rational Corporation), Sybase (acquired by SAP in 2010 for $5.8 billion), Vertica (acquired by HP), VistaPrint (Nasdaq: VPRT) and WebLine Communications (acquired by Cisco Systems).
Before co-founding Highland, Paul was a general partner at Charles River Ventures where he concentrated on software investments. Prior to entering venture capital, he held operating positions for six years in high-growth technology companies. At Novacor Corporation he worked on the development of an implantable artificial heart. Later, Paul was responsible for the development of a complex visual field examination instrument at Synemed Corporation where he also headed the company's mechanical engineering and software development. Earlier in his career, Paul was the Energy Analyst at Brown University.
Paul received a M.B.A. with distinction from Harvard Business School, a M.S. in Mechanical Engineering from Stanford University and a B.S.E. in Aerospace and Mechanical Science from Princeton University.
General Partner, ProQuest Investments
Mr. Moorin is a founding General Partner at ProQuest. He is a healthcare executive with senior management experience in biotech, investment banking and pharmaceutical industry. Prior to founding ProQuest, Jay served as CEO of Magainin Pharmaceuticals (now Genaera Corp.). Previously, he was Managing Director of Health Care Banking at Bear, Stearns & Co. Jay has also held various positions in strategy and general management at E.R. Squibb & Sons Pharmaceuticals. He has served on the Board of Directors of ACMI, Epic Therapeutics, Gloucester Pharmaceuticals, Guava Technologies, Mersana Therapeutics, Novacea (now Transcept) and Pharmion. Currently, he serves on the Board of Directors of Acurian, Aires Pharmaceuticals, Eagle Pharmaceutical, MethylGene and Predictive Biosciences.
Jay holds the position of Adjunct Senior Fellow of the Leonard Davis Institute of Health Economics at the University of Pennsylvania. He received a B.A. in economics with distinction from the University of Michigan.
Julia Dyckman Andrus Professor, Harvard Medical School and Director, Vascular Biology Program, Children's Hospital Boston
Dr. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Children's Hospital Boston. Marsha also leads the Urinary Proteomics Initiative first established in her laboratory, the focus of which is the identification and validation of non-invasive biomarkers for human cancers.
Marsha is an internationally recognized expert in the regulation of angiogenesis and leads a research group that conducts both basic and translational research. She and her group have discovered many different angiogenesis inhibitors, several of which are being developed for clinical use. Her research provided some of the earliest proof linking matrix metalloproteinases to successful angiogenesis.
Marsha has authored more than 100 peer-reviewed publications, including articles in Science, Cell, the Journal of Biological Chemistry and The New England Journal of Medicine. She has presented over 100 lectures to national and international audiences. Marsha holds approximately 70 patents, both issued and pending, in the United States, Canada, Europe and Asia. Her awards and honors include the Cancer Research Foundation Award, the American Cancer Society Research Award, and the Center for Excellence in Women's Health Research Award from Harvard Medical School. In 2008, she was elected to the prestigious Institute of Medicine of the National Academy of Sciences, one of the highest honors in the fields of health and medicine. Marsha earned her Ph.D. from Boston University.
Chief Executive Officer, Predictive Biosciences
Mr. Cassigneul has more than 25 years of senior management experience in the healthcare and medical device industries, both in Europe and the United States. Previously, Pierre was vice chairman of the board and formerly president and chief executive officer of XDx Inc. Under his leadership, XDx received Food and Drug Administration (FDA) clearance for and launched the AlloMap® Gene Expression Test for use in transplant management, representing one of the first U.S. molecular diagnostics company to obtain FDA approval of an in vitro diagnostic multivariate index assay (IVDMIA). He joined XDx from the consulting firm, Stone Bridge Management LLC, where he was an operating partner. Formerly, as the vice president of diabetes management at Becton Dickinson & Co, he oversaw completion of the product, clinical trials and regulatory submissions. Pierre has held top management positions at Bayer in the diabetes self-testing business unit, where he developed and launched a new patient-monitoring system; Ortho Diagnostic Systems (J&J) in the AIDS and hepatitis business unit, where he launched a complete line of blood screening products; and Abbott Laboratories in the diagnostic division, where he launched the first HIV test for screening the European blood supply. He served on the board of The Personalized Medicine Coalition. He holds a management degree from the Ecole Superieure de Commerce de Reims, France.